Space Stock Face-Off: Is Rocket Lab or AST SpaceMobile Worth Your Money Right Now?

Rocket Lab reported Q1 revenue of $200.3 million, up 63.5% year over year, and beat on sales, earnings, and guidance, but still posted a $0.07 per-share loss and burned $77.4 million in free cash flow. AST SpaceMobile missed on all three key metrics, with Q1 revenue of $14.7 million versus $37.5 million expected and a $0.66 per-share loss versus a $0.21 loss expected, while guiding to about $175 million in full-year revenue. The article is constructive on Rocket Lab relative to AST, but remains cautious on both stocks given ongoing losses and stretched valuations.

Analysis

The market is still rewarding “space exposure” as a category, but the earnings divergence is starting to separate asset-light narrative names from businesses that are actually compounding operating leverage. RKLB’s better execution matters less for the quarter itself than for what it implies about launch cadence and adjacent-services attach rates: if it can keep filling more of the stack, margin expansion should eventually come from mix, not just scale. That said, the stock is still being priced as if path-to-profitability is a financing problem solved by growth alone, when the real issue is whether Neutron and acquisitions can convert backlog into durable free cash flow before capital intensity re-accelerates.

ASTS is the cleaner short on fundamentals, but the more interesting risk is not the miss itself; it is the gap between capital deployment and monetization. When a company is burning hundreds of millions before service launch dates are firm, the equity behaves less like a telecom buildout and more like a binary project-finance instrument — every delay pushes dilution risk higher and compresses the value of future optionality. The satellite-loss headline also increases the probability that execution slippage, not demand, becomes the binding constraint over the next 2-3 quarters.

The second-order loser may be the broader “Space IPO / pre-profit tech infrastructure” basket: once one or two high-multiple names miss, factor investors tend to de-rate the entire cluster on cash-burn duration rather than on TAM. That creates an opportunity for relative-value trades, because RKLB and ASTS are not the same business quality despite both trading on space enthusiasm. Consensus is likely underappreciating how quickly sentiment can rotate from “category premium” to “show me cash conversion” if the SpaceX IPO opens a cleaner comp set at a lower multiple than the current froth implies.

Key Decisions for Investors

• Short ASTS on rallies over the next 2-6 weeks; use call spreads or a defined-risk put spread to express downside toward the next financing/delay catalyst. Risk/reward favors the short because each month of launch slippage increases dilution probability and erodes the terminal value of the spectrum thesis.
• Relative-value pair: long RKLB / short ASTS for 1-3 months. RKLB has the clearer execution path and less binary cash-burn risk; the pair isolates quality dispersion inside the same thematic basket with lower market-direction exposure.
• Avoid buying RKLB outright until post-Q2 guidance clarity or a meaningful pullback; if initiated, prefer staged entries on weakness because the market is still capitalizing profitability too early. Upside is better over 12-24 months than over the next 1-2 quarters.
• Watch for a broader de-rating in pre-profit aerospace/defense infrastructure names if ASTS continues to slip; use any such selloff to rotate toward profitable satellite supply-chain beneficiaries rather than the platform names themselves.
• If SpaceX IPO pricing comes in below the current private-market narrative, fade the entire space-beta basket for 1-2 weeks around the deal; lower-than-expected comp multiples could compress RKLB/ASTS valuation multiples even without any company-specific news.